Gebrüder Weiss takes over Ipsen Logistics' Air & Sea business | DC Velocity
Press Releases - Ipsen UK
Press Releases - Ipsen UK
Combined Shareholders' Meeting of 27 May 2021
FOP Fnd NL on X: "Ipsen Initiates Partial Clinical Hold for Palovarotene IND120181 and IND135403 Studies ...for children under the age of 14 because of some cases with early growth plate closure...
Press Releases - Ipsen UK
Global Biopharmaceutical Company, Ipsen Announces New Headquarters for North America will be located in Cambridge, Massachusetts | Financial Post
Ipsen media library
Press Releases - Ipsen UK
Ipsen (@IpsenGroup) / X
Emirates Oncology Society And Ipsen Break Guinness World Record For Largest Awareness Ribbon | Press Release Network
Press Releases / Melissa Peebles
Ipsen to acquire exclusive rights to investigational ERK inhibitor as part of its existing research collaboration with AGV Discovery | Liberi Group
Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases
Ipsen CEO David Loew is elected to EFPIA leadership; joins industry partners to warn of impact of EU pharma legislation - Global
Mayoly Spindler completed the acquisition of Ipsen's CHC branch - MAYOLY SPINDLER laboratoire indépendant français
Ipsen Goes All In on Neuro with $1 Billion+ Deal For Exicure's Oligonucleotides | BioSpace
Press Releases - Ipsen UK
IPSEN: Announces FDA Approval of Dysport® (abobotulinumtoxinA) for the Treatment of Upper Limb Spasticity in Children, Excluding Cerebral Palsy | FDA Reporter
Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership
06-01-2016-PR-Ipsen-Galderma-APAC-Dysport-Aesthetics
Ipsen: Patients Living with Spasticity Want Long-lasting Symptom Relief | Business Wire
Ipsen is officially recognized as a great place to work worldwide - Global
LeaveRussia: Ipsen is Pausing New Investments in Russia
Press Releases - Ipsen UK
